Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.

: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first intravesical application of VPM1002BC in human.

[Epidemiology and strategy to prevent urinary catheters related complications].

Indwelling urinary catheter (IUC) is encountered in every four admitted in-patients. The risk of bacteriuria increases by 3‑7 % every day and is almost universal at 30 days. Of these, 10 % will develop symptomatic infection, bacteremia, septic choc or death.

[« Doctor, I have a little erection problem ! »].

Erectile dysfunction (ED) is a common condition that affects nearly one in three men age 50 and more than one in two after 70 years. It is often multifactorial and shares risk factors with coronary heart disease, which is an early marker. Its management involves an etiological research, a modifiable risk factors correction and often a treatment with phosphodiesterase type 5 inhibitors (IPDE-5).

Prospective evaluation of early postoperative male and female sexual function after radical prostatectomy with erectile nerves preservation.

Prostate cancer screening has led to the diagnosis of localized prostate cancer in increasingly young and sexually active men. Accordingly, the impact of cancer treatment on sexual function is gaining more attention. To prospectively evaluate the impact of radical prostatectomy (RP) on male, female and conjugal sexual function.